DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 36.7% from a year ago
Total assets stood at $53.08M at the end of Q1 FY2026, up 36.7% from a year earlier and down 13.5% from the prior quarter. Over 3 fiscal years it compounded at +21.3% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +36.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 61.37M USD
- Year-over-year change
- +32.4%
- 4-year CAGR
- +7.7%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 61.37M | +32.4% |
| FY2024 | 2024-12-31 | 46.35M | -14.4% |
| FY2023 | 2023-12-31 | 54.16M | +57.5% |
| FY2022 | 2022-12-31 | 34.4M | -24.5% |
| FY2021 | 2021-12-31 | 45.55M | — |
Total Assets vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 total assets of $53.08M is the lowest of the 7 companies compared; the peer median is $380.09M.
- Its year-over-year change of +36.7% is the 2nd highest of 7, against a peer median of +16.3%.
- Over three fiscal years its annual growth of +21.3% compares with a peer median of +20.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Jun 2026 | $1.16B | -0.7% | -7.8% | |
| Mar 2026 | $419.71M | +26.1% | +38.4% | |
BIOABioAge Labs, Inc. | Mar 2026 | $397.65M | +15.7% | +118.1% |
| Mar 2026 | $362.52M | +16.9% | +1.9% | |
| Mar 2026 | $292.78M | -27.9% | -13.5% | |
| Mar 2026 | $64.41M | +130.5% | +159.3% | |
| Mar 2026 | $53.08M | +36.7% | +21.3% | |
| Peer median (excluding DMAC) | $380.09M | +16.3% | +20.1% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.